Illumina to sequence Frozen Zoo’s five-decade biobank, creating multiomic conservation resources
- Illumina announced a large-scale sequencing collaboration to convert Frozen Zoo's preserved cells into actionable genomic resources.
- Illumina will deploy sequencing and multiomic tools to generate genomic data for wildlife medicine, evolution, and biodiversity conservation.
- Illumina and the Frozen Zoo will make sequencing outputs a shared resource for conservation, enabling comparative genomics and population analyses.
Illumina links Frozen Zoo’s five-decade archive to modern genomics
Illumina is announcing a large-scale sequencing collaboration with the San Diego Zoo Wildlife Alliance’s Frozen Zoo, aiming to convert decades of preserved cells from threatened and endangered animals into actionable genomic resources. The agreement covers sequencing of up to 4,000 samples that represent roughly 1,300 unique species and individual animals from the Frozen Zoo’s archive, which the partners describe as one of the world’s most comprehensive biodiversity biobanks.
Sequencing archived cells to power conservation genomics
Under the pact, Illumina deploys its sequencing and multiomic capabilities to generate genomic and multi-layer molecular data intended to inform wildlife medicine, evolutionary biology and biodiversity preservation. The project uses a subset of historical samples for integrated multiomic research — combining genome sequencing with other molecular assays — to create datasets that conservation practitioners, researchers and policy makers can apply to population management, species recovery and ecological resilience efforts.
Illumina frames the work as a demonstration of how scalable sequencing technologies can activate the latent value in long-term biobanks. Cande Rogert, vice president and global head of Advanced Sciences at Illumina, says the collaboration shows multiomic technologies “activate the potential of critical biodiversity biobanks.” By linking sample metadata collected over five decades with modern genomic profiles, the partners expect to generate reference resources that support diagnostics, breeding decisions and inferred demographic histories for at-risk taxa.
The Frozen Zoo’s vice president of conservation science, Megan Owen, says the partnership marks a “new era of genomic discovery” that accelerates capacity to halt and reverse biodiversity loss. She frames the next 50 years of the Frozen Zoo as reliant on a global network of conservation scientists and scalable multiomic platforms to maximize the research and practical impact of biobanked samples.
Broader industry and conservation implications
The agreement highlights a growing trend in which commercial sequencing providers extend services into conservation genomics, applying high-throughput technologies originally developed for human and agricultural genomics to wildlife and ecosystem challenges. Observers say the resulting datasets can improve monitoring of genetic diversity, inform translocation and captive-breeding programs, and support policy decisions grounded in molecular evidence.
Technical and operational scope
Illumina and the Frozen Zoo expect sequencing outputs to become a shared resource for the conservation community, with data products aimed at enabling comparative genomics, population structure analyses and other multiomic investigations. The partners emphasize that converting stored cellular material into standardized genomic resources is central to making long-term biobanks more immediately useful to field and policy applications.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…